CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Exploration With Blinatumomab and CAR T-Cell Therapy Continues in ALL

December 22nd 2019

Joseph Wynne, MD, discusses ongoing studies with blinatumomab and CAR T-cell therapy in acute lymphoblastic leukemia, as well as the importance of assessing minimal residual disease in this space.

Real-World Analysis Shows Cost-Reducing Benefit With CAR-T in Relapsed DLBCL

December 20th 2019

Karl M. Kilgore, PhD, discusses how results of real-world analysis may impact the utilization of CAR T-cell therapy for older patients with relapsed/refractory diffuse large B-cell lymphoma.

FDA Approval Sought for Liso-Cel in Large B-Cell Lymphoma

December 19th 2019

Bristol-Myers Squibb has submitted a biologics license application to the FDA seeking approval of the anti-CD19 CAR T-cell therapy lisocabtagene maraleucel for the treatment of adult patients with relapsed/refractory large B-cell lymphoma after at least 2 prior therapies.

Dr. Park on Potential Alternate CAR T-Cell Targets in B-Cell Malignancies

December 14th 2019

Jae H.Park, MD, discusses potential alternate CAR T-cell targets in B-cell malignancies.

Characteristics, Healthcare Utilization, and Costs of Medicare Patients Receiving CAR T-Cell Therapy

December 13th 2019

Karl M. Kilgore, PhD, senior research scientist, Avalere Health, discusses real-world data regarding Medicare patients with non-Hodgkin lymphoma receiving CAR T-cell therapy.

Updated bb21217 Data Continue to Impress in Multiple Myeloma

December 11th 2019

The CAR T cell therapy bb21217 demonstrated high very good partial response or better rates in patients with heavily pretreated relapsed/refractory multiple myeloma.

Dr. Perales on the Future of CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 10th 2019

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Dr. Madduri on the Results of the CARTITUDE-1 Trial in Multiple Myeloma

December 9th 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the results of the phase Ib/II CARTITUDE-1 trial of the BCMA-directed CAR T-cell therapy JNJ-4528 in patients with heavily pretreated relapsed/refractory multiple myeloma.

Early Steroid Use Reduces Risk of Cytokine Release Syndrome With Axi-Cel

December 9th 2019

Steroid use while cytokine release syndrome and neurologic toxicities are at grade 1, instead of waiting until grade 3, reduces the rate of CAR T-cell treatment–related CRS and neurologic events.

Dr. Abramson on Safety and Efficacy of Liso-Cel in Relapsed/Refractory Large B-Cell Lymphoma

December 9th 2019

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the pivotal safety and efficacy results from phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory large B-cell lymphoma.

Liso-Cel Induces High Rate of Durable Responses in LBCL

December 9th 2019

CD19-directed CAR T-cell therapy induced a high rate of rapid and durable complete responses in patients with aggressive relapsed/refractory large B-cell lymphoma.

Axi-Cel Elicits 47% 3-Year OS Rate in B-Cell Lymphoma

December 8th 2019

The CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) induced a median overall survival of 25.8 months for patients with refractory large B-cell lymphoma.

CAR-T Progress Continues in Non-Hodgkin Lymphoma, But Guidelines Need Updating

December 3rd 2019

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Dr. Perales on CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 3rd 2019

Miguel-Angel Perales, MD, discusses the use of CAR T-cell therapy in diffuse large B-cell lymphoma and transformed follicular lymphoma.

Dr. Garfall Discusses CAR T-Cell Therapy in Multiple Myeloma

November 22nd 2019

Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.

Dr. Perales on Ongoing Studies With CAR T Cells in DLBCL

November 16th 2019

Miguel-Angel Perales, MD, discusses replacing autologous stem cell transplant with CAR T-cell therapy in diffuse large B-cell lymphoma.

Dr. Park on Updates With CAR T Cells in ALL

November 1st 2019

Jae H. Park, MD, discusses encouraging data with CAR T-cell therapy in acute lymphoblastic leukemia.

Dr. Shah on CAR T-Cell Therapy in Pediatric ALL

October 10th 2019

Nirali N. Shah, MD, MHSc, discusses the use of CAR T-cell therapy in pediatric patients with acute lymphocytic leukemia.

Dr. Sasine on Predicting Individual Benefit with CAR T Cells

October 9th 2019

Joshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.

Improving CAR T-Cell Therapies With Greater Understanding of Cancer Immunology

October 8th 2019

Eduardo Sotomayor, MD, discusses the evolution of CAR T-cell therapy, adverse events that require careful monitoring, and novel strategies under development that may mitigate toxicity and improve T-cell persistence.